Taken together, our results show that KAT2A inhibition does not exhibit adverse effects on hematopoietic stem-progenitor cells and offers itself as a potential anti-AML therapeutic strategy for future studies. This evidence concerns the gene KAT2A and acute myeloid leukemia.